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Abstract
Lyme neuroborreliosis (LNB) is a serious but treatable disease. The diagnosis of LNB poses a challenge to clinicians, and improved
tests are needed. The C6-peptide ELISA is frequently used on serum but not on cerebrospinal ﬂuid (CSF). Data on the sensitivity of
the C6-peptide ELISA in CSF in patients suffering from LNB have been conﬂicting. Serum–CSF pairs from 59 LNB patients, 36 Lyme
non-neuroborreliosis cases, 69 infectious meningitis/encephalitis controls and 74 neurological controls were tested in a C6-peptide
ELISA. With the optimal cut-off of 1.1, the sensitivity of the C6-peptide ELISA for LNB patients in CSF was 95%, and the speciﬁcity was
83% in the Lyme non-neuroborreliosis patients, 96% in the infectious controls, and 97% in the neurological controls. These results
suggest that the C6-peptide ELISA has a high sensitivity and good speciﬁcity for the diagnosis of LNB patients in CSF. The C6-peptide
ELISA can be used on CSF in a clinical setting to screen for LNB.
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Introduction
Lyme neuroborreliosis (LNB) is the neurological manifesta-
tion of an infection with the tick-borne spirochete Borrelia
burgdorferi sensu lato (sl). LNB can present with many
neurological signs, varying from facial nerve paralysis
and Bannwarth’s syndrome to a range of neurological
disorders [1,2]. The diagnosis of LNB poses a challenge to
clinicians. Detecting B. burgdorferi sl directly by culture or
by PCR from cerebrospinal ﬂuid (CSF) yields a maximum
sensitivity of only about 50% [3]. A standard method
for diagnosing LNB is determination of the intrathecal
speciﬁc antibody index (AI), despite the fact that the
sensitivity of the AI has been reported to vary from 48%
to 92% [4,5].
A peptide of interest for diagnosing LNB has been the
immunoreactive peptide C6, a highly conserved peptide
among different B. burgdorferi sl [6].
C6-peptide is the sixth invariable region of the VlsE pro-
tein. The vls locus consists of 15 silent vls cassettes and the
gene for the VlsE lipoprotein. By application of unidirectional
recombination events, VlsE can display antigenic variation [7].
The C6-peptide has been shown to be an immunodominant
peptide [8]. IgG antibodies to C6-peptide have been shown
to be detectable as early as 2 weeks post-infection, and anti-
bodies wane over time after treatment [6,9]. The sensitivity
and speciﬁcity of the C6-peptide ELISA in serum have been
reported to be equal, if not superior, to those of two-tier
testing in North American patients [10,11]. C6-peptide
serology has been shown to have high sensitivity in LNB
patients, varying from 67% to 100% [12,13]. The commer-
cially available C6-peptide ELISA has been validated only for
serum samples. Data on the performance of the C6-peptide
ELISA performed on CSF for the diagnosis of LNB are lim-
ited and conﬂicting [14–16]. The aim of this study was to
determine whether a C6-peptide-based ELISA can be
used on CSF samples to diagnose early and late LNB
patients, using a large cohort of well-deﬁned patients and
controls.
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Materials and Methods
Selection of clinical specimens and control samples
Patients and controls from the time period between January
2004 and October 2009 were identiﬁed retrospectively by
use of the laboratory information management system from
the Leiden University Medical Centre (Leiden), OLVG Hospi-
tal (Amsterdam), the IZORE Centre for Infectious Diseases
(Leeuwarden), the Academic Medical Centre Amsterdam
(Amsterdam), and the Isala clinic (Zwolle). CSF–serum pairs
from 59 LNB patients were included. Criteria for diagnosing
LNB patients were four of the following ﬁve: (i) detection of
B. burgdorferi antibodies in serum; (ii) CSF pleocytosis (>5/
lL); (iii) absence of other evident cause of meningitis; (iv)
evidence of intrathecal production of speciﬁc B. burgdorferi
antibodies; and (v) objective neurological complaints with
favourable outcome after treatment [17]. Thirty-six CSF–
serum samples were available from Lyme borreliosis (LB)
patients who did not have LNB according to the applied
algorithm. The LB patient group consisted of 12 recent ery-
thema migrans (EM) patients, 21 Lyme arthritis patients, and
three acrodermatitis chronica athrophicans patients. CSF and
serum samples were available from 69 patients with other
infectious diseases, 62 CSF–serum pairs were collected from
patients with neurological inﬂammatory diseases, and 12
CSF–serum pairs were collected from patients with neuro-
logical complaints, including dizziness, headache and fatigue
without evident diagnosis, and trauma patients (Table 1).
Additional data were collected for all patient groups: age at
presentation, sex, duration of illness (>6 months was classi-
ﬁed as late LNB), and CSF ﬁndings at diagnosis (intrathecal
leukocytes and erythrocytes per microlitre, percentage of
mononuclear cells, glucose level, total protein, IgG, and albu-
min). For LNB patients, the clinical presentation, duration of
complaints and report of an EM were documented.
C6-peptide ELISA
All sera and CSF samples were tested with the C6 Lyme
ELISA Kit (Immunetics, Boston, MA, USA). Preliminary
results showed good performance of a 1 : 5 dilution for CSF.
Therefore, and for practical reasons, all CSF samples were
tested in a 1 : 5 dilution with the manufacturer’s protocol
for serum. C6-peptide ELISA was performed on sera accord-
ing to the manufacturer’s protocol. The Lyme index (LI) was
calculated according to the manufacturer’s protocol: absor-
bance450–650 nm sample/[(absorbance450–650 nm calibrator) +
0.3]. Samples with LI values <0.9 were to be considered neg-
ative, those with LI values 0.9–1.1 equivocal, and those with
LI values ‡1.1 positive for antibodies against C6-peptide in
serum.
AI
All sera and CSF samples were tested with the IDEIA Lyme
Neuroborreliosis kit, according to the manufacturer’s proto-
col (Oxoid, Ely, UK). The AI was calculated as (optical den-
sity (OD)CSF/ODserum) · (ODCSF ) ODserum). The CSF was
considered to contain IgG or IgM if the ODCSF IgG or IgM
was >0.150. The AI was considered to be positive when the
CSF was positive and the AIIgG or AIIgM was ‡0.3.
TABLE 1. Epidemiological characteristics of patient groups and baseline cerebrospinal ﬂuid (CSF) leukocyte count (per lL)
n
Male/female
ratio (%)
Mean age
(years) (SD)
Mean CSF leukocyte count
(per lL of CSF) (SD)
Lyme neuroborreliosis 59 60/40 39 (24) 135 (159)
Lyme borreliosis 36 50/50 51 (17) 1 (1)
Infectious meningitis/encephalitis controls 69
Treponema pallidum 12 83/17 40 (8) 40 (79)
Cryptococcus neoformans 2 50/50 52 (6) 94 (89)
Bacterial meningitis
Streptococcus pneumoniae 2 50/50 41 (6) 337 (99)
Listeria monocytogenes 1 0/100 61 1280
Mycobacterium tuberculosis 1 0/100 4 25
Viral meningitis/encephalitis
HIV 6 50/50 43 (8) 51 (45)
VZV 11 45/55 51 (23) 130 (173)
HSV1 6 33/67 55 (30) 46 (51)
Enterovirus 23 61/39 13 (17) 271 (381)
Parechovirus 3 0/100 0 (0) 1 (1)
TBE 2 50/50 37 (4) 59 (12)
Neurological controls 74
Facial nerve paralysis eci 19 66/34 48 (18) 40 (145)
Multiple sclerosis 26 35/65 35 (14) 15 (17)
Polyneuritis/polyneuropathy 16 56/44 45 (17) 17 (22)
ADEM 1 0/100 21 266
Neurological non-inﬂammatory controls 12 25/25 47 (13) 4 (6)
ADEM, acute disseminated encephalomyelitis; HIV, human immunodeﬁciency virus; HSV1, herpes simplex virus 1; TBE, tick-borne encephalitis; VZV, varicella zoster virus; SD,
standard deviation.
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Statistical analysis
Statistical analysis was performed with a statistical software
package (SPSS for Windows, version 17.0). Student’s t-test
was used to compare levels of C6-peptide LI between
groups, and p-values <0.05 were considered to be signiﬁcant.
Results
Patient characteristics
All patient serum and CSF samples were tested according to
protocol. Patient epidemiological data are represented in
Table 1. The group of LB and LNB patients showed a bimo-
dal distribution of age, with a peak in childhood and a peak
at 55 years. Of the 59 LNB cases, 20% reported an EM at
presentation. Clinical presentation consisted most frequently
of facial nerve paralysis (58%) and meningoradiculitis (27%);
the remainder of the cases presented with malaise and head-
ache (10%), meningoencephalitis, and a sensation of altered
vision with papillo-oedema. Most patients had early dissemi-
nated LNB (53/59). Four of the six patients with late LNB
presented with meningoradiculitis of duration between
6 months and 2 years. Two patients had suffered for 6–
18 months from an altered gait with magnetic resonance
imaging abnormalities. Ninety-ﬁve per cent of patients pre-
sented with pleocytosis. Only two patients presenting with
early LNB, one with facial nerve paralysis and one with men-
ingoradiculitis, and one patient presenting with late LNB,
with meningoradiculitis, did not have pleocytosis. These
three patients eventually all had antibodies against B. burgdor-
feri in serum and CSF, and the AI was positive. Furthermore,
they all responded favourably to treatment.
The AI in the IDEIA neuroborreliosis kit detected anti-
Borrelia IgG or IgM in 78% of the LNB patients. The IgG AI
was positive in 75% and the IgM AI was positive in 49% of
the LNB patients (Table 2).
C6-peptide ELISA results on serum
The results for the C6-peptide ELISA are shown in Fig. 1.
C6-peptide antibodies were detected in serum in 98% of the
LNB patients, with a mean LI of 8.4 (95% conﬁdence interval
(CI) 7.7–9.1). The one C6-peptide ELISA-negative patient
was a young child with early LNB presenting with facial
paralysis with an elevated CSF leukocyte count (236/lL). In
this patient, the CSF showed detectable antibodies in the
C6-peptide ELISA (LI 8.7) as well as a positive AI in the
IDEIA for IgG and IgM. The patients who presented with
early LNB had a comparable LI in serum to that of the
patients who presented with late LNB, with a respective
mean LI of 8.3 and 9.1 (p 0.5). In the non-neuroborreliosis
LB patient group, the sensitivity was 97%, and the mean
LI was 6.9 (95% CI 5.6–8.2). In all other controls, the
C6-peptide seroprevalence was 5%.
C6-peptide ELISA results on CSF
The sensitivity and speciﬁcity for the C6-peptide ELISA on
CSF are shown in Table 3. The C6-peptide ELISA on CSF
detected antibodies in 95% (56/59) of the LNB patients. The
patients who presented with early LNB had a lower LI in
CSF than the patients who presented with late LNB, with
respective mean LIs of 6.6 (95% CI 5.6–7.3) and 8.6
(95% CI 7.3–10.3) (p <0.01). Two patients did not have
detectable antibodies in the CSF, a child and an adult. Both
had early LNB with facial nerve paralysis at presentation.
The adult patient presented with right facial paralysis, but did
not have pleocytosis at presentation and had a negative AI.
Antibodies against C6-peptide were already present in the
serum at presentation (LI 9.2). Diagnosis was later substanti-
ated when he presented with bilateral facial paralysis and
conclusive CSF serology. The child had antibodies against
C6-peptide (LI 9.4), and IgM was detected in the IDEIA, but
both AIs were negative in the CSF. At presentation, she had
pleocytosis of 56/lL CSF, and she responded rapidly to
treatment. The third patient, a borderline (LI 0.9) positive
patient, had pleocytosis of 31 leukocytes/lL and complaints
of dysarthria with a high IgM AI and an elevated IgG AI.
Antibodies against C6-peptide in serum were detectable
(LI 6.8).
Speciﬁcity in all controls varied from 83% to 97% (Table 3).
Speciﬁcity was high in the infectious and neurological control
TABLE 2. Results of the antibody index from the IDEIA, showing the number of samples that were negative or positive for
IgM and IgG against ﬂagellin in cerebrospinal ﬂuid, and the index calculated as described (Ig and Ig index are the results of the
IgM and IgG results combined per patient)
Negative (%) IgM+ IgG+ IgM index+ IgG index+ Ig+ (%) Ig index+ (%) Total
Lyme neuroborreliosis 1 (2) 52 49 29 44 58 (98) 46 (78) 59
Lyme borreliosis 26 (72) 3 8 10 (38) 36
Infectious controls 61 (88) 7 1 2 8 (12) 2 (3) 69
Neurological controls 70 (95) 3 1 1 4 (5) 1 (1) 74
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groups (96% and 97%, respectively). In the infectious control
group, there were no controls with detectable antibodies
against C6-peptide in the serum, but three controls had
detectable levels in the CSF. These controls were an enterovi-
rus meningitis patient, a neurosyphilis patient, and a human
immunodeﬁciency virus meningitis patient. In the neurological
control group, seven patients had detectable antibodies against
C6-peptide in serum; these were ﬁve multiple sclerosis (MS)
patients and two Guillian–Barre´ patients. In the CSF, two MS
patients had low levels of detectable antibodies against C6-
peptide (LI 1.4–1.8). In the LB group alone, the speciﬁcity was
83% (30/36). Values of the C6-peptide ELISA in CSF were sig-
niﬁcantly higher in the LNB than in the LB cases (mean LIs of
6.7 (95% CI 6.0–7.6) and 0.8 (95% CI 0.3–1.4), respectively,
p <0.05). Lowering the LI threshold to 0.5 would increase the
sensitivity to 97% in LB patients, but lower the speciﬁcity to
63%. No effect was seen on the speciﬁcity in the other
controls.
Discussion
In this study, we evaluated the C6-peptide ELISA on CSF for
diagnosing LNB infection. We found a high sensitivity as well
as a good speciﬁcity of the C6-peptide ELISA.
We chose an algorithm deﬁning LNB patients where an
LNB patient could either have absence of pleocytosis or
absence of intrathecal antibody production in the presence
of an abundance of other criteria that made LNB evident.
C6-peptide serology has good sensitivity in LNB patients,
varying from 67% to 100% in serum [12–14,18]. The lower
sensitivities were mainly reported in very early LNB, when
the duration of symptoms was <8 days. The sensitivity of the
C6-peptide ELISA on serum of LNB patients in this study
was 98%. The serum from one child with early LNB was
negative for anti-C6-peptide antibodies in the ELISA. In previ-
ous studies, it was demonstrated that patients with LNB can
have an early response to the ﬂagellin antigen, which can be
detectable earlier intrathecally than in serum, leading to
reports of seronegative LNB [19,20]. This ﬁnding had not
been substantiated for the C6-peptide ELISA until now.
In this study, we found 95% sensitivity of the C6-peptide
ELISA on CSF for diagnosing LNB. Previously, two European
publications using the C6-peptide ELISA have determined the
sensitivity of the C6-peptide ELISA on CSF, and the data
have been conﬂicting. Skarpaas et al. used undiluted CSF and
a cut-off of OD 0.5, which is comparable to the LI value of
0.9 as compared with the OD/cut-off standard used in the
present kit. This cut-off is comparable to the borderline cut-
off in our study. Prospectively, 60 adult LNB patients,
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FIG. 1. Values for the C6-peptide ELISA in
serum (a) and cerebrospinal ﬂuid (b).
Horizontal lines indicate medians, bars
represent interquartile ranges, lines represent
95% conﬁdence intervals, and bullets represent
outliers. The reference line is located at the
cut-off for detection of antibodies (Lyme index
(LI) = 1.1). LNB, Lyme neuroborreliosis.
TABLE 3. Lyme index (LI) values of the C6-peptide ELISA
in cerebrospinal ﬂuid; samples with LI values <0.9 are con-
sidered to be negative for antibodies against C6-peptide, LI
values 0.9–1.1 equivocal and LI values ‡1.1 positive for anti-
bodies against C6-peptide
Anti-C6-
peptide-
negative (%)
Equivocal
(%)
Anti-C6-
peptide-
positive (%) Total
Lyme neuroborreliosis 2 (3) 1 (2) 56 (95) 59
Lyme borreliosis 29 (81) 1 (3) 6 (17) 36
Infectious controls 66 (96) 3 (4) 69
Neurological controls 72 (97) 2 (3) 74
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deﬁned as having clinical LNB, pleocytosis, and evidence of
intrathecal anti-Borrelia IgG production by ELISA, were tested
in the C6-peptide ELISA and a sensitivity of 98% on CSF was
found. The C6-peptide ELISA was also performed on CSF
from 42 controls in whom the speciﬁcity was 88% [14].
Another study used diluted and undiluted CSF with LI cut-
offs of 0.5 and 1 [16]. Retrospectively, 31 tentative cases of
LNB were identiﬁed by evidence for intrathecal antibody pro-
duction obtained by western blot. Twenty-eight LNB patients
were identiﬁed according to clinical presentation and concur-
rent clinical response to antibiotic treatment. The sensitivity of
the C6-peptide ELISA in these patients was only 61%, which is
lower than the previously reported sensitivity and our ﬁndings.
The low sensitivity found in that study may be explained by the
inclusion of non-LNB patients in the study group. Clinical data,
including CSF ﬁndings, were not provided. Furthermore, the
use of immunoblots to determine intrathecal antibody
responses is problematic, and can lead to overdiagnosis [21–
23]. In addition, it has been reported that up to 20% of patients
who have detectable antibodies against B. burgdorferi sl and
respond to treatment do not have LNB but have other self-
limiting conditions [24,25]. It is likely that the low sensitivity of
the C6-peptide ELISA reported resulted from a poorly deﬁned
LNB patient group.
The speciﬁcity of the C6-peptide ELISA on CSF for detect-
ing LNB was 88% in previously reported studies. In the current
control group, the speciﬁcity varied from 83% to 97%, with the
lowest speciﬁcity being seen in the LB patient group (83%). In
the infectious and neurological control groups, the speciﬁcities
were 96% and 97%, respectively. Passively acquired antibodies
from the serum could explain the detectable anti-C6-peptide
antibodies in the CSF. However, in the infectious control
group, none of the analysed controls with antibodies in the
CSF had anti-C6-peptide antibodies in the serum. In the neuro-
logical control group, only two MS patients had detectable
antibodies in the CSF. Production of polyclonal Ig in the CSF
because of MS might also be an explanation for the false-posi-
tive result in these patients. Calculation of the C6-peptide AI
with the IgM/IgG C6-peptide ELISA was not possible, because
it was a combined IgM and IgG ELISA. Because no actual AI
could be calculated, the speciﬁcity of the C6-peptide ELISA
with CSF will, by deﬁnition, be suboptimal in patients with
detectable anti-Borrelia antibodies in the serum, as no correc-
tion is made for passively acquired antibodies in the CSF.
A shortcoming of this study is that it is a retrospective
study, which might have led to selection bias. The strength
of this study, however, lies in the number and wide variety
of the controls. Many samples were selected from patient
groups in whom the clinical presentation could be mistaken
for LNB. The LNB and control groups also included patients
from all age groups. On the basis of the previous publica-
tions, the speciﬁcity of the C6-peptide ELISA for diagnosing
LNB on CSF was insufﬁciently investigated.
In interpreting serology results, a combination of duration
of complaints, patient history, and knowledge of laboratory
parameters, e.g. pleocytosis in LNB, is essential for a correct
diagnosis to be reached. In a Lyme-endemic region, antibod-
ies can be detected in patients who do not suffer from
neuroborreliosis. When faced with the clinical situation
wherein diagnosis of LNB seems to be less probable, with
detectable anti-C6-peptide in the CSF, it can be useful to use
a more speciﬁc assay, such as calculating a speciﬁc AI.
In conclusion, we show good sensitivity and speciﬁcity of
the C6-peptide ELISA on CSF. The C6-peptide ELISA is a
reliable screening test that can be used in serum and CSF to
assist in the diagnosis of LNB.
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